These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K Transplantation; 2006 May; 81(10):1390-7. PubMed ID: 16732175 [TBL] [Abstract][Full Text] [Related]
10. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Fang B; Song YP; Liao LM; Han Q; Zhao RC Bone Marrow Transplant; 2006 Sep; 38(5):389-90. PubMed ID: 16878145 [No Abstract] [Full Text] [Related]
11. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy. Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371 [TBL] [Abstract][Full Text] [Related]
12. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Marshall SR Nat Clin Pract Oncol; 2006 Jun; 3(6):302-14. PubMed ID: 16757968 [TBL] [Abstract][Full Text] [Related]
13. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
14. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173 [TBL] [Abstract][Full Text] [Related]
15. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Fang B; Song Y; Lin Q; Zhang Y; Cao Y; Zhao RC; Ma Y Pediatr Transplant; 2007 Nov; 11(7):814-7. PubMed ID: 17910665 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Auletta JJ; Cooke KR Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239 [TBL] [Abstract][Full Text] [Related]
17. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
18. Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Scaife MD; Neschadim A; Fowler DH; Medin JA Expert Opin Biol Ther; 2009 Jun; 9(6):749-61. PubMed ID: 19456209 [TBL] [Abstract][Full Text] [Related]
19. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290 [TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]